Gozellix performance for imaging of biochemically recurrent prostate cancer appears to be affected by serum PSA levels and site of disease; for imaging of metastatic pelvic lymph nodes prior to ...
The FDA has approved a new formulation of an F 18 prostate-specific membrane antigen imaging agent for men with prostate ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between ...
Biohaven (NYSE:BHVN) shares traded higher on Wednesday after the company said its antibody-drug conjugate BHV-1510 with cemiplimab, an anti-PD-1 therapy marketed by Regeneron (NASDAQ:REGN) as Libtayo, ...
Tumors often contain areas of oxygen-deficient tissue that frequently withstand conventional therapies. This is because the drugs applied in tumors require oxygen to be effective. An international ...
Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a treatment for two tumor conditions linked to kidneys. Accordingly, the oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results